Conference Calendar

March 14-18 - American Association of Orthopaedic Medicine Annual Meeting 2017

March 14-December 31 - Canaccord Genuity Musculoskeletal Conference

Complete Calendar »

Earnings Calendar

No Upcoming Events Scheduled
Complete Calendar »

Read our research via:
email art

Weekly Email

rss art

RSS



app icon

iPhone

app store icon

Kindle



Orthopedic and Dental Industry News Complete Archive »

Kuros Regains Biomaterials Rights from Baxter BY LAUREN UZDIENSKI, NOVEMBER 15, 2010

Kuros announced that they have regained the rights to three biomaterials that were in development with Baxter. The original agreement was signed in 2005 and related to combining Baxter's Tisseel fibrin sealant with Kuros' technology.

The materials in question (known as KUR-112, KUR-212 and KUR-213) are intended for orthopedic and wound-healing applications. KUR-112 consists of a protein derivative of human parathyroid hormone, which can aid in the formation of bone, and is in development for the treatment of solitary bone cysts. The technology, which at the time was intended to be delivered with Baxter's Tisseel, received orphan drug designation from the FDA in 2007 as well as a similar orphan designation in the EU.

Though Kuros said they planned to initiate a clinical study of KUR-112 in 2007, the company has not provided further updates to the public on the status of that study. Presumably, Kuros is in the market for another carrier for the technology, though the company has so far kept quiet on future development plans.

Baxter will retain development and commercialization rights to other Kuros technologies, including KUR-111, which is being studied in tibial plateau fractures, and KUR-113, being studied in open tibial shaft fractures. Both studies are currently in phase IIB. The press release did not say why the KUR-112, KUR-212 and KUR-213 rights were being returned, even as Baxter is considerably broadening its biologics offering with the recent acquisition of ApaTech.

Email this to a colleague: